These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 9113492)

  • 1. Post-transplant diabetes mellitus. The role of immunosuppression.
    Jindal RM; Sidner RA; Milgrom ML
    Drug Saf; 1997 Apr; 16(4):242-57. PubMed ID: 9113492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?
    Egidi FM
    Drugs; 2005; 65(2):153-66. PubMed ID: 15631539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
    Wagner K; Webber SA; Kurland G; Boyle GJ; Miller SA; Cipriani L; Griffith BP; Fricker FJ
    J Heart Lung Transplant; 1997 Mar; 16(3):275-82. PubMed ID: 9087870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.
    Shivaswamy V; Boerner B; Larsen J
    Endocr Rev; 2016 Feb; 37(1):37-61. PubMed ID: 26650437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.
    Plosker GL; Foster RH
    Drugs; 2000 Feb; 59(2):323-89. PubMed ID: 10730553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive drug-induced diabetes.
    Penfornis A; Kury-Paulin S
    Diabetes Metab; 2006 Dec; 32(5 Pt 2):539-46. PubMed ID: 17130815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus.
    Prokai A; Fekete A; Pasti K; Rusai K; Banki NF; Reusz G; Szabo AJ
    Pediatr Diabetes; 2012 Feb; 13(1):81-91. PubMed ID: 21595806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating mechanisms of post-transplant diabetes mellitus.
    van Hooff JP; Christiaans MH; van Duijnhoven EM
    Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi8-vi12. PubMed ID: 15575024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus in transplant rejection.
    Rath T
    Expert Opin Pharmacother; 2013 Jan; 14(1):115-22. PubMed ID: 23228138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.
    Spencer CM; Goa KL; Gillis JC
    Drugs; 1997 Dec; 54(6):925-75. PubMed ID: 9421697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for and management of post-transplantation cardiovascular disease.
    Fellström B
    BioDrugs; 2001; 15(4):261-78. PubMed ID: 11437691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment.
    Wissing KM; Pipeleers L
    Transplant Rev (Orlando); 2014 Apr; 28(2):37-46. PubMed ID: 24507957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant diabetes mellitus: the last 10 years with tacrolimus.
    Bäckman LA
    Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi13-vi16. PubMed ID: 15575021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
    Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
    Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreas transplantation for diabetes mellitus: a guide to recipient selection and optimum immunosuppression.
    Stratta RJ; Alloway RR
    BioDrugs; 1998 Nov; 10(5):347-57. PubMed ID: 18020607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.